ZA91274B - Controlled absorption naproxen formulation for once-daily administration - Google Patents

Controlled absorption naproxen formulation for once-daily administration

Info

Publication number
ZA91274B
ZA91274B ZA91274A ZA91274A ZA91274B ZA 91274 B ZA91274 B ZA 91274B ZA 91274 A ZA91274 A ZA 91274A ZA 91274 A ZA91274 A ZA 91274A ZA 91274 B ZA91274 B ZA 91274B
Authority
ZA
South Africa
Prior art keywords
once
daily administration
naproxen
controlled absorption
naproxen formulation
Prior art date
Application number
ZA91274A
Other languages
English (en)
Inventor
Edward Anthony Bourke
Anthony Bourke Edward
Seamus Mulligan
Mulligan Seamus
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11007725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA91274(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Publication of ZA91274B publication Critical patent/ZA91274B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA91274A 1990-01-15 1991-01-14 Controlled absorption naproxen formulation for once-daily administration ZA91274B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE14990A IE66933B1 (en) 1990-01-15 1990-01-15 Controlled absorption naproxen formulation for once-daily administration

Publications (1)

Publication Number Publication Date
ZA91274B true ZA91274B (en) 1991-10-30

Family

ID=11007725

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA91274A ZA91274B (en) 1990-01-15 1991-01-14 Controlled absorption naproxen formulation for once-daily administration

Country Status (15)

Country Link
US (1) US5637320A (es)
EP (1) EP0438249B1 (es)
JP (1) JP3157182B2 (es)
AT (1) ATE126055T1 (es)
AU (1) AU639519B2 (es)
CA (1) CA2034096C (es)
DE (1) DE69111832T2 (es)
DK (1) DK0438249T3 (es)
ES (1) ES2075338T3 (es)
GR (1) GR3017633T3 (es)
IE (1) IE66933B1 (es)
IL (1) IL96900A (es)
NZ (1) NZ236762A (es)
PH (1) PH30694A (es)
ZA (1) ZA91274B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
EP0859603B1 (en) 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DE19715594A1 (de) * 1997-04-15 1998-10-22 Bayer Ag Analgetika-Kombination
EA002806B1 (ru) 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US20040259895A1 (en) * 1998-05-28 2004-12-23 Medical Research Institute Oral formulation of lipid soluble thiamine and lipoic acid
WO2000004879A1 (en) * 1998-07-24 2000-02-03 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
KR100463496B1 (ko) 1999-09-30 2005-01-06 펜웨스트 파머슈티칼즈 컴파니 고가용성 약물용 서방성 메트리스 시스템
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
CA2398555C (en) * 2000-01-27 2008-04-22 Tanabe Seiyaku Co., Ltd. Sustained release preparation and method for producing the same
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10211289A1 (de) 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
WO2004024184A1 (ja) 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
SI21301A (sl) * 2002-09-11 2004-04-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
CN1726012A (zh) * 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
US20040228918A1 (en) * 2003-01-02 2004-11-18 Chih-Ming Chen Granule modulating hydrogel system
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
EP1753405A4 (en) * 2004-06-10 2008-09-17 Glatt Air Tech Inc SLOW RELEASE PHARMACEUTICAL PREPARATION
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
US20060078621A1 (en) * 2004-10-13 2006-04-13 Wedinger Robert S Method of providing customized drug delivery systems
WO2007011972A2 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
MX2008000967A (es) * 2005-07-20 2008-03-26 Panacea Biotec Ltd Nueva composicion farmaceutica de forma de dosis de liberacion modificada que comprende inhibidor de enzima ciclooxigenasa.
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
AU2007267612A1 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US20090104236A1 (en) * 2007-10-18 2009-04-23 Pharmaceutics International, Inc. Pharmaceutical solid hybrids
AU2008343787B2 (en) 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
CA2765866C (en) * 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
CN101411702B (zh) * 2008-11-29 2010-12-29 河南大学 盐酸奈福泮萘普生钠复方缓释制剂及其制备方法
MX2011007819A (es) * 2009-01-22 2011-12-16 Abbott Healthcare Private Ltd Composicion farmaceutica cronoterapeutica.
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms
CN103118669B (zh) * 2010-06-01 2016-01-13 盖斯特里希医药公司 口服药物治疗方法和组合物
KR101160645B1 (ko) * 2010-11-12 2012-06-29 (주)게임콘어뮤즈먼트 미니 앨범 제작 장치
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
PL3054929T3 (pl) 2013-10-07 2021-05-31 Impax Laboratories, Llc Mukoadhezyjne preparaty lewodopy i / lub estrów lewodopy o kontrolowanym uwalnianiu oraz ich zastosowania
CN106414415A (zh) 2014-03-14 2017-02-15 北卡罗来纳大学教堂山分校 用于抑制雄性生育力的小分子
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
EP0212745B1 (en) * 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US4783937A (en) * 1986-08-06 1988-11-15 Shimizu Construction Co., Ltd. Device for suppressing vibration of structure
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung

Also Published As

Publication number Publication date
IE66933B1 (en) 1996-02-07
ES2075338T3 (es) 1995-10-01
DK0438249T3 (da) 1995-09-18
EP0438249A1 (en) 1991-07-24
IE900149A1 (en) 1991-07-17
CA2034096C (en) 2002-03-26
DE69111832T2 (de) 1996-03-14
AU639519B2 (en) 1993-07-29
PH30694A (en) 1997-09-16
JPH04217918A (ja) 1992-08-07
ATE126055T1 (de) 1995-08-15
GR3017633T3 (en) 1996-01-31
US5637320A (en) 1997-06-10
CA2034096A1 (en) 1991-07-16
IL96900A (en) 1995-12-31
AU6933291A (en) 1991-07-18
EP0438249B1 (en) 1995-08-09
JP3157182B2 (ja) 2001-04-16
NZ236762A (en) 1992-12-23
DE69111832D1 (de) 1995-09-14
IL96900A0 (en) 1992-03-29

Similar Documents

Publication Publication Date Title
PH30694A (en) Controlled absorption naproxen formulation for once-daily administration.
IL209703A0 (en) Controlled release hydrocodone formulations
ZA874577B (en) New galenic formulations with programmed release containing antiphlogistics
CA2116238A1 (en) Oral 1 .alpha.-hydroxyprevitamin d
AU8696191A (en) Formulations and their use in the treatment of neurological diseases
AP9400645A0 (en) Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release sold dosage forms of medicaments prepared thereby.
DE69533492D1 (de) Orale Metoprolol-Dosisform des Typs "einmal täglich"
IL106253A0 (en) Controlled release oral solid pharmaceutical dosage form and its preparation
SI0642788T1 (en) Tramadol salt containing medicaments with sustained release of the active ingredient
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
GR3034186T3 (en) 3,4-diarylchromans for treatment of dermatitis
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
DK0524696T3 (da) Orale præparater indeholdende dapiprazol
CA2064112A1 (en) .alpha.-dihydroergocryptine pharmaceutical preparations with neuroprotective activity
GR3031360T3 (en) Composition based on ibuprofen, for oral usage